Didronel is used to treat osteoporosis (thinning of bone) in women after menopause, even though this medication has not yet been approved by the FDA specifically for this purpose. After menopause, there is an increased rate of bone loss (resorption), and an increased risk of bone fractures. In these patients, didronel has been shown to increase bone density while strengthening bone, and decrease the rate of bone fractures. Didronel is also helpful in the treatment of Paget's disease of the bone. The cause of Paget's disease is unknown. It is characterized by a disorderly and accelerated remodeling of the bone, leading to bone weakness and pain. Didronel reduces bone pain and fractures in Paget's disease. Didronel is also used to prevent an unusual condition, called heterotopic ossification. In heterotopic ossification, bone is deposited in soft tissues and muscles, usually after hip replacement or spinal cord surgery.
Active Ingredients: Etidronic acid
Didronel Indication & Mechanism Of Action